Clovis Oncology Inc. picked up another clinical-stage compound to add to its pipeline of cancer products. The Boulder, Colo.-based company will pay an undisclosed upfront fee to Pfizer Inc., plus potential milestones of $255 million, in exchange for the right to develop and commercialize the drug. In turn, Pfizer Venture Investments will make an equity investment in Clovis.